Fusen

Quick links to important sections

Fusen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fusen

Quick Facts

Property Description
Active ingredient Acetylsalicylic acid (ASA)
Form Oral solid dosage form (e.g., tablet)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID) and Antiplatelet Agent
General purpose Relief of pain and fever; modification of blood clotting
Origin Synthetic (salicylate derivative)

Fusen is a pharmaceutical preparation defined by its active compound, Acetylsalicylic acid (ASA), which places it within the salicylate chemical family. ASA is a medicine clinically recognized for its analgesic and anti-inflammatory properties. This active substance is officially categorized as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is widely recognized for its anti-thrombotic capabilities, acting as an Antiplatelet Agent. Acetylsalicylic acid is included in recognized lists of essential medicines, confirming its global role in fundamental healthcare.


What is Fusen and Its Dual Classification?

Fusen is a medication whose core substance is Acetylsalicylic acid (ASA), which functions as a single-ingredient product. This dual classification is critical to its identity: it is an effective NSAID while simultaneously possessing unique anti-clotting properties. This dual function is significant because the compound's mechanism, depending on the context, delivers two distinct benefits: acting against pain and inflammation, and modifying the process of blood coagulation. This makes it a crucial compound in managing general discomfort, such as for the temporary relief of a tension headache.


Composition, Origin, and Dosage Form

Fusen is manufactured as a synthetic compound, originating from chemical processes rather than direct natural extraction, categorizing it as a salicylate derivative. Its composition involves the active ingredient Acetylsalicylic acid combined with essential pharmaceutical excipients (such as binders and coatings). It is typically supplied as an oral solid dosage form—such as a tablet or capsule—for subsequent oral administration. Acetylsalicylic acid works by blocking the substance in the body that causes pain and inflammation. This confirms that the medicine’s chemical structure is directly responsible for its core effects on the body.


Fusen’s General Therapeutic Purpose and Action

The overarching purpose of Fusen is to modify key biological responses in the body, primarily by providing general symptomatic relief from minor pain and reducing an elevated fever. It achieves these functions by interfering with the body's local production of specific chemical messengers (prostaglandins). Furthermore, its capacity for inhibiting platelet aggregation provides a critical function related to regulating blood flow. This dual action is a core differentiator, supporting its wide application from general analgesia to long-term modulation of the clotting process.

Regulatory References

  1. National Institutes of Health (NIH)
  2. U.S. National Library of Medicine
  3. MedlinePlus

What side effects are possible with Fusen?

Fusen: Possible side effects and safety information

This section summarizes the officially documented adverse reactions and safety information for Fusen, strictly as reported in government regulatory documents from agencies like the FDA and EMA.

Regulatory Safety Highlights

The most significant safety information is communicated via a Boxed Warning concerning Embryo-Fetal Toxicity. This mandatory restriction informs that Fusen may cause fetal harm when administered to a pregnant woman. Consequently, use is prohibited in women of reproductive potential who cannot comply with specific risk mitigation measures.

Adverse Reactions and System-Organ Classes

The overall safety profile is primarily documented by frequency-classified adverse reactions observed during clinical trials. These events are categorized by incidence and body system (System-Organ Class).

Key categories of adverse reactions documented in official prescribing information include:

  • General Disorders and Administration Site Conditions: This group includes Infusion-Related Reactions, which are acute events that may occur during or shortly after administration and require specific management protocols.
  • Blood and Lymphatic System Disorders: Adverse events in this class include various Hematological Abnormalities.
  • Investigations: This category captures changes in laboratory tests, including severe Grade 3 or 4 Laboratory Abnormalities.

Clinically Significant and Common Adverse Reactions

The regulatory documents classify adverse reactions based on their frequency. The Most Common Adverse Reactions (those occurring most frequently in clinical trials) provide the primary overview of the drug's expected risk profile. Additionally, the label details Serious Adverse Reactions that warrant particular attention, though specific frequency bands (e.g., 'Very Common,' 'Common,' 'Uncommon') organize the full list of reported events. The official safety information establishes a definitive regulatory understanding of the medicine's risks without providing clinical recommendations.

Overdose and Emergency Response

Fusen overdose, also known as Salicylate Toxicity, presents with a documented range of clinical manifestations. Early signs listed in regulatory documents typically include tinnitus (ringing in the ears), nausea, vomiting, and hyperventilation (rapid or deep breathing). As toxicity progresses, severe physiological outcomes may occur, such as profound acid-base disturbances (e.g., metabolic acidosis), significant hyperthermia, and serious neurological effects including confusion, seizures, or coma.


Scope of Overdose Manifestations Official Regulatory Status
Documented Severe Outcomes Severe systemic effects, including cerebral edema, noncardiogenic pulmonary edema, and respiratory failure, are documented in labeling.
Antidote Information No specific antidote is known for Salicylate Toxicity; management is defined as symptomatic and supportive.
Population Note The profile notes that toxicity can be particularly severe in the elderly and in children, requiring specialized consideration.

Immediate medical attention must be sought for any suspected or confirmed overdose, according to regulatory guidance. This profile mandates that due to the potential for rapid clinical deterioration and severe life-threatening complications, contacting emergency services is the required action when toxicity is suspected. Treatment is primarily supportive, focusing on physiological stabilization and enhancing the drug’s elimination.

Therapeutic Uses of Fusen

What Fusen Treats: Main Uses and Benefits

Fusen (acetylsalicylic acid) is generally used across multiple therapeutic domains, addressing both symptomatic needs and prophylactic support. Its application is common in areas where short-term symptom management is appropriate.

Dual Therapeutic Focus

The medication is relevant for easing symptoms related to physical discomfort such as headaches, muscle aches, and menstrual cramps, and it is commonly used to help with an elevated body temperature (fever). Additionally, it is considered relevant in conditions involving inflammatory or irritative processes, including rheumatoid arthritis and osteoarthritis.

Its second application involves prophylactic support for managing risk related to cardiovascular events in high-risk patients, addressing conditions like a history of heart attack or clot-related stroke. In these scenarios, Fusen helps patients cope more steadily with temporary discomfort, and it contributes to easing the overall symptom load associated with heightened physiological activity.

“The primary benefit is offering symptomatic relief that helps patients cope more steadily with temporary discomfort or may assist with maintaining functional stability related to heightened physiological activity.”


Quick Fact: Relief for Episodic Discomfort

Primary Function Therapeutic Use
Analgesic / Antipyretic Easing acute, episodic discomfort and assisting with an elevated body temperature.
Anti-inflammatory Supporting patients during difficult episodes of chronic inflammation.
Antiplatelet Addressing the risk of certain serious, recurrent vascular manifestations.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Fusen (Enfuvirtide) — Official Regulatory Information


Contraindications

Fusen is absolutely contraindicated in patients with a known hypersensitivity to enfuvirtide or any of its components. Use must also not be restarted in any patient who has previously experienced systemic signs of a hypersensitivity reaction.


Age and Population Restrictions

Population Category Eligibility Status (Regulatory Basis)
Adults and Adolescents Approved for use (typically ge 16 years)
Children Approved for use (typically ge 6 years) but must weigh at least 11 kg
Children under 6 years Not recommended; safety and efficacy are not established
Geriatric Patients No specific dose adjustment is required, but there is limited clinical experience in patients over mathbf65 years.

Physiological and Comorbidity Restrictions

  • Pregnancy: Use is permitted only if the potential benefit justifies the potential risk to the fetus, as human data are limited.
  • Lactation (Breastfeeding): Not recommended due to the potential risk of HIV-1 transmission to the infant and unknown excretion of the drug into breast milk.
  • Renal Impairment: No dose adjustment is required in patients with a creatinine clearance ge 35 mL/min, including those on dialysis.
  • Hepatic Impairment: No dose recommendation can be established for patients with hepatic impairment due to a lack of available data.
  • Coagulation Disorders: Patients with hemophilia or those receiving anticoagulants may have an increased risk of post-injection bleeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Fusen (Acetylsalicylic acid, ASA) is structured around official regulatory findings concerning its antiplatelet effects and metabolic clearance pathways.

Documented Interaction Patterns

Interacting Agents or Conditions Official Interaction Pattern (Regulatory Description)
Anticoagulants/Other Antiplatelets (e.g., Warfarin, Clopidogrel) Pharmacodynamic reinforcement resulting in a significantly increased risk of bleeding events.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (e.g., Ibuprofen) Increased risk of gastrointestinal (GI) bleeding and ulceration due to additive irritation. Ibuprofen can also compromise ASA's intended cardioprotective benefits.
Methotrexate Co-administration may result in reduced clearance, leading to elevated and/or prolonged serum levels of Methotrexate.
Diuretics / Antihypertensives (e.g., ACE Inhibitors, Furosemide) Co-administration may diminish the intended natriuretic or antihypertensive therapeutic effects.

Specific Restrictions and Considerations

Official labeling mandates a specific timing separation for certain co-administrations; for instance, Ibuprofen must be administered at least 8 hours before or 30 minutes after immediate-release ASA to mitigate interference with its antiplatelet effect. A specific Alcohol Warning is documented for chronic, heavy consumption (three or more drinks per day), noting a substantial increase in the risk of GI bleeding. Furthermore, elderly patients and individuals with renal impairment are identified in regulatory documents as populations at greater risk for clinically significant GI events or drug accumulation.

Mechanism of Action

Core Mechanism: Irreversible Enzyme Inhibition

Fusen's action begins at the molecular level with its single active ingredient, Acetylsalicylic acid (ASA), which acts as an irreversible inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes. By covalently modifying a specific binding site on the enzyme, the drug permanently disables the COX activity, effectively halting the synthesis of messenger molecules known as prostanoids from the Arachidonic Acid Cascade. This sustained blockade initiates all downstream physiological effects, including the modulation of thermal regulation, nociceptive signaling, and platelet function.

Dual Modulation of Thermal and Nociceptive Pathways

The resulting suppression of prostanoid synthesis, particularly Prostaglandin E2 (PGE2), acts on two distinct regulatory systems. Centrally, the mechanism alters the thermal set point of the hypothalamus, a process that affects systemic thermal regulation. Peripherally, the reduced availability of PGE2 at nerve endings acts to modulate nociceptive signaling, affecting the peripheral sensitization of pain receptors.

Sustained Alteration of Platelet Function

The mechanism is unique in its effect on blood clotting due to the cellular constraints of platelets. Once the COX-1 enzyme within a platelet is irreversibly inhibited, the platelet cannot synthesize new enzyme protein, leading to a permanent suppression of Thromboxane A2 (TXA2) production for the entire lifespan of that platelet. This mechanism results in a prolonged alteration of the platelet's capacity for aggregation, affecting blood flow dynamics.

Dosage and Administration Information

How to Use Fusen

Fusen (Acetylsalicylic acid) is administered via the oral route, available in multiple solid forms including standard tablets and specialized modified-release capsules. Usage is defined by two fundamentally different dosing patterns, establishing separate parameters for intermittent and continuous administration.

Standard Administration Patterns

Use Pattern Single Dose Range Frequency and Duration
Symptomatic Relief (High Dose) 300 mg to 1000 mg Every 4 to 6 hours as needed; typically short-term use, not to exceed 3–4 days for pain or fever.
Continuous Management (Low Dose) 75 mg to 162.5 mg Once daily (q24h) as a continuous, long-term regimen.

The maximum recommended dose for symptomatic relief is generally restricted to 4000 mg over a 24-hour period. For acute ischemic events, an initial loading dose between 150 mg and 450 mg may be administered.

Procedural Requirements and Constraints

All dosage forms should be taken with a full glass of water. To help mitigate potential gastrointestinal intolerance, the medicine may be taken with or after a meal. A critical procedural constraint is that modified-release forms, such as enteric-coated or extended-release tablets, must be swallowed whole and must not be cut, crushed, or chewed, as this alters the intended drug release profile. If a scheduled once-daily dose is missed, the standard procedure is to take it as soon as remembered on the same day, but a double dose should not be taken.

Population Use Boundaries

Fusen is generally not recommended for children and adolescents under 16 years of age. While the standard adult dose is often used in older adults, caution is advised, and the medicine is generally avoided in patients with severe hepatic or renal impairment.

Recent Clinical Evidence

Fusen: Recent Clinical Evidence

Overview of Targeted Research

Fusen is studied as a targeted therapy investigated across various conditions characterized by specific gene fusions or molecular irregularities. Clinical research focuses on assessing its activity in tumors or diseases expressing these unique fusion proteins. Studies often involve non-randomized or single-arm designs in patient groups for whom standard treatments have not been successful.

Efficacy and Response Rates

Research has explored the drug's activity in different solid tumors and in certain rare neurological conditions, with outcomes measured by objective response rates (ORR) or changes in disease biomarkers. For example, some Phase 2 trials in specific fusion-positive cancers have evaluated tumor shrinkage, with initial data suggesting ORRs in a subset of participants. The duration of this measured response is also a key metric examined in ongoing studies.

Measured Outcome Typical Study Design Key Findings Focus
Tumor Size/Activity Single-arm Phase 2/3 Percentage of participants showing a reduction in tumor size
Adverse Events All Trials Incidence and severity of treatment-related side effects
Pharmacokinetics Phase 1/2 How the body absorbs, distributes, and eliminates the drug

Safety and Tolerability Profile

Safety endpoints are a primary focus in all phases of the research. Clinical trials have characterized the spectrum of adverse events reported by participants, which may include gastrointestinal issues, fatigue, or infusion-related reactions. Trial protocols include monitoring for specific laboratory abnormalities and determining the maximum tolerated dose. Information regarding the long-term safety of the drug is still being gathered through extension studies and post-marketing surveillance.

Current Status

Fusen (or its active component) has regulatory approval for use in select indications. Further studies are required to confirm its clinical benefit and long-term outcomes across all populations where the relevant gene fusion is identified.

Frequently Asked Questions (FAQ)

Common questions about Fusen (FAQ)


Q: How long does the effect of one dose of Fusen typically last?

Studies and official information indicate that the time the effect lasts depends on the purpose of use. The dosing frequency for analgesic and fever-reducing effects is typically described as every 4 to 6 hours. For its effect on blood clotting (antiplatelet effect), the action is irreversible and persists for the entire lifespan of the affected platelet, which is typically 7 to 10 days.


Q: Are there certain foods or drinks I should avoid while using Fusen?

Regulatory documents state that chronic, heavy alcohol use (three or more drinks per day) may substantially increase the risk of gastrointestinal (GI) bleeding when taken with this medication. The official product information specifies that the medicine may be taken with or after food, which can help mitigate potential stomach irritation.


Q: Is it possible to take Fusen if I am also taking an over-the-counter pain reliever?

Regulatory information indicates that the active ingredient, ASA, is sometimes used concurrently with non-NSAID relievers like acetaminophen (Paracetamol). However, taking it with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen, is generally not recommended by regulatory agencies due to an increased risk of side effects like stomach bleeding.


Q: Is there a maximum time someone can stay on Fusen?

The official product information specifies two general use patterns. Use for pain and fever relief is restricted to short-term use, typically 1 to 3 days. The duration of continuous long-term regimens is not specified as a fixed maximum in regulatory documents.


Q: Do studies suggest that Fusen is generally well-tolerated?

Regulatory safety data characterizes adverse reactions based on the incidence and severity observed in clinical trials. The most common side effects reported typically involve mild issues like indigestion and stomach ache. Official documents establish the risk profile without using subjective terms like 'well-tolerated'.


Q: Can older adults use Fusen safely?

Official labeling states that caution should be exercised when the medication is used in older adults, even though no specific dose adjustment is required. Older individuals are identified in regulatory documents as a population at greater risk for clinically significant gastrointestinal events and bleeding.


Q: Is it normal to feel a change in energy levels after starting Fusen?

Fatigue is a treatment-related adverse event documented in regulatory summaries of clinical trials. The official information does not classify a change in energy levels as a 'normal' expected patient experience. A healthcare professional should be consulted regarding unexpected changes in energy levels.


Q: Is it true that Fusen must be taken at a specific time of day?

For continuous management, the medication is usually prescribed to be taken once daily (q24h). Furthermore, if co-administration with certain NSAIDs like ibuprofen occurs, official guidance specifies that a specific timing separation is necessary to prevent interference with the antiplatelet effect.


Q: What's the difference between Fusen and other drugs used for the same purpose?

Acetylsalicylic acid (ASA), the active ingredient in Fusen, has a dual classification as both a Nonsteroidal Anti-inflammatory Drug (NSAID) and an Antiplatelet Agent. Official information describes that it differs from many other NSAIDs due to its mechanism of irreversible inhibition of the COX enzyme in platelets. This mechanism is what provides a permanent, long-lasting effect on blood clotting.


Q: Are there different forms of Fusen (e.g., tablet, liquid)?

According to the official product information, the medication is available in multiple solid forms. These include standard tablets, specialized modified-release forms like enteric-coated tablets and capsules, and dispersible tablets. A liquid form is not addressed in these regulatory summaries.


Q: Has Fusen been studied in diverse patient populations?

Clinical trials, such as the ASPREE study, have enrolled large patient populations to assess the drug's overall risk and benefit. These studies provide information relevant to the use of the drug in a variety of patient groups, including older adults across different geographic regions.


Q: How quickly does Fusen start working after I take it?

Clinical trial data suggests that the full antiplatelet effect of a standard oral dose is typically achieved in about 74 minutes. However, the onset time for the analgesic (pain-relieving) and antipyretic (fever-reducing) effects is generally faster, though the exact timing can vary between individuals.


Q: What kind of interactions does Fusen have with common supplements like multivitamins?

Official information indicates that salicylates, the active class of the medication, can interfere with the action of Vitamin K and may alter the synthesis of certain coagulation factors. It is important that a prescribing physician is informed about all supplements being taken.


Q: Will Fusen affect my ability to drive or operate machinery?

The medication may cause side effects such as dizziness or drowsiness. Regulatory guidance recommends that awareness of one's reaction to the medication is maintained before driving or operating machinery or vehicles.


Q: Is Fusen available under different brand names?

Studies and official information indicate that the active ingredient in Fusen is Acetylsalicylic acid (ASA). This compound is the active substance in a globally recognized pain relief medication, and it is available worldwide under many different brand names and generic labels.


Q: Does Fusen affect sleep patterns?

While not a primary purpose, low-dose acetylsalicylic acid has been investigated in clinical research for its effects on inflammation associated with restricted sleep. Some findings suggest a potential reduction in wake after sleep onset (WASO), but this is not a labeled indication for the drug.


Q: Can I stop taking Fusen suddenly, or do I need to taper off?

Regulatory guidance strongly warns against abrupt cessation. If the medication is being taken for cardiovascular disease prevention, abruptly stopping therapy is associated with a significantly increased risk of serious cardiovascular events. Discontinuation of the medication should always be discussed with a healthcare professional.


Q: Are headaches a common side effect of Fusen?

Headaches are listed in patient information as a potential adverse reaction. This is particularly noted when the medication is used for short-term pain relief. All reported adverse events are detailed in the 'Possible side effects' section of the official product information.


Q: How often do people using Fusen report feeling dizzy?

Dizziness is a reported adverse event. Official safety information specifies that if dizziness or ringing in the ears (tinnitus) occurs, it may be an early sign of taking too much of the drug (overdose). The occurrence of such events, which can be a sign of toxicity, warrants immediate consultation with a healthcare professional.


Q: Does Fusen affect fertility?

Clinical research has investigated the effects of low-dose acetylsalicylic acid on reproductive processes, particularly in women attempting conception. Some studies have suggested a potential impact on the successful establishment of pregnancy, although this is a specialized area of research.


Q: Can people with diabetes use Fusen?

Low-dose use of the medication is sometimes associated with a lower risk of major cardiovascular events in adults with Type 2 diabetes. This association is typically studied in patients who are already identified as being at an elevated risk of heart disease or stroke.


Q: How long has Fusen been approved by major health agencies?

The active ingredient in Fusen, Acetylsalicylic acid (ASA), is a long-standing and well-established drug. It is among the world’s longest-used medicines, having first been synthesized in a pure and stable form over a century ago in 1897.

How should Fusen be stored and disposed of?

Official Storage and Environmental Conditions

Fusen (acetylsalicylic acid) must be stored in its original package and the container kept tightly closed to maintain product stability. Storage is required at a temperature not exceeding 25 °C (or 77 °F) in a dry place. The medicine must be explicitly protected from moisture and excessive heat, as exposure can cause chemical degradation (hydrolysis), which may be indicated by a vinegar odor. The product must not be frozen.

Disposal and Child Safety

It is a mandatory requirement that the medication be kept out of the sight and reach of children. For disposal, any unused medicinal product or waste material must be managed in accordance with local requirements. The product should not be released into the environment (such as drains or wastewater); it must be managed through appropriate pharmaceutical waste channels, often an approved waste disposal plant.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fusen found in:

A-Z Index: